# Dermata Therapeutics (DRMA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/DRMA
## Company Profile
- Ticker: DRMA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 1.17 USD
- Market cap: 5470114.48 USD
- Last updated: 2026-08-05
## Business Overview
### Consumer Skincare Company
Dermata Therapeutics has shifted from clinical-stage dermatology development toward a direct-to-consumer commercial skincare strategy.
### Tome Brand
Tome is designed as a professional-style at-home skincare line built around simplified, periodic treatments rather than multi-step daily regimens.
### Foundational Treatment
The first planned product is a once-weekly mask intended to support skin renewal and serve as the foundation of the broader Tome portfolio.
## Why The Stock Is Moving

Following the latest company update, “Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment”, DRMA closed up 6.36% at $1.17 on Aug 5, 2026. The move occurred in the trading session associated with this commercial update.

## Future Catalysts

- Dermata plans to launch the Tome Foundational Treatment in mid-2026.

## Recent News
- 2026-08-05 12:30 EST — [Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment](https://biopharmsignal.com/news/DRMA/dermata-therapeutics-announces-commercial-launch-date-for-tome-tm-foundational-t-11e4aa47) — Source: Dermata Therapeutics
- 2026-05-13 20:05 EST — [Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026](https://biopharmsignal.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-financial-results-for-the-first-quarter-2026) — Source: Dermata Therapeutics
- 2026-04-02 12:30 EST — [Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System](https://biopharmsignal.com/news/DRMA/dermata-receives-notice-of-acceptance-of-australian-patent-application-for-topical-application-of-dermal-fillers-with-its-bioneedle-delivery-system) — Source: Dermata Therapeutics
- 2026-03-26 21:15 EST — [Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025](https://biopharmsignal.com/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-financial-results-for-the-year-ended-2025) — Source: Dermata Therapeutics
- 2026-03-10 12:30 EST — [Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing](https://biopharmsignal.com/news/DRMA/dermata-announces-appointment-of-kyra-peckaitis-as-vice-president-marketing) — Source: Dermata Therapeutics